Altimmune, Inc. (NYSEARCA:ALT) Director Derace L. Schaffer bought 33,315 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was acquired at an average cost of $1.91 per share, for a total transaction of $63,631.65. Following the purchase, the director now owns 274,238 shares of the company’s stock, valued at $523,794.58. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Altimmune, Inc. has a 1-year low of $49.37 and a 1-year high of $54.24.
Separately, Piper Jaffray Companies began coverage on shares of Altimmune in a research note on Monday, October 9th. They issued an “overweight” rating and a $6.00 target price on the stock.
TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/03/altimmune-inc-alt-director-buys-63631-65-in-stock.html.
iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.
What are top analysts saying about Altimmune Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Altimmune Inc. and related companies.